Cell Genesys’ New Data Bolster GVAX Survival Mechanism
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II antibody responses – two, so far – help “peel the onion,” chief financial officer tells “The Pink Sheet” DAILY.
You may also be interested in...
Takeda, Cell Genesys Ink $270 Million GVAX Deal For Prostate Cancer
Oncology, urology areas are important to the firm because of huge unmet needs, Takeda tells “The Pink Sheet” DAILY.
Takeda, Cell Genesys Ink $270 Million GVAX Deal For Prostate Cancer
Oncology, urology areas are important to the firm because of huge unmet needs, Takeda tells “The Pink Sheet” DAILY.
Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009
Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.